David M Brown Selected Research

aflibercept

1/2022	INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial.
1/2022	KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.
1/2022	MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
9/2021	Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
5/2021	Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial.
1/2020	Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.
1/2020	HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration.
12/2019	Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial.
12/2019	Higher-Order Assessment of OCT in Diabetic Macular Edema from the VISTA Study: Ellipsoid Zone Dynamics and the Retinal Fluid Index.
10/2018	Evaluating the Impact of Intravitreal Aflibercept on Diabetic Retinopathy Progression in the VIVID-DME and VISTA-DME Studies.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David M Brown Research Topics

Disease

46	Macular Edema 01/2022 - 03/2007
34	Macular Degeneration (Age-Related Maculopathy) 01/2022 - 10/2006
21	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2022 - 03/2007
14	Retinal Vein Occlusion 01/2018 - 06/2010
12	Inflammation (Inflammations) 10/2022 - 01/2003
7	Endophthalmitis (Ophthalmia) 01/2020 - 10/2006
6	Choroidal Neovascularization 05/2021 - 10/2006
5	Neoplasms (Cancer) 01/2017 - 07/2005
5	Infections 05/2013 - 02/2004
4	Stroke (Strokes) 01/2018 - 04/2012
3	Edema (Dropsy) 01/2018 - 01/2014
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017 - 04/2009
3	Uveitis 03/2013 - 10/2006
3	Necrosis 09/2011 - 01/2003
2	Ischemia 06/2020 - 01/2013
2	Geographic Atrophy 01/2020 - 04/2011
2	Ischemic Stroke 01/2018 - 04/2012
2	Atrophy 01/2018 - 01/2013
2	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 07/2005
2	Nausea 01/2017 - 08/2012
2	Hemorrhage 01/2016 - 10/2007
2	Malaria 04/2013 - 01/2003
2	Prostatic Neoplasms (Prostate Cancer) 08/2010 - 07/2005
1	Carotid-Cavernous Sinus Fistula 01/2022
1	Retinal Vasculitis 01/2022
1	Diabetes Mellitus 01/2021
1	Cataract (Cataracts) 10/2018
1	Body Weight (Weight, Body) 01/2018
1	Choroidal Effusions 01/2018
1	Retinal Diseases 08/2017
1	Fatigue 01/2017
1	Anorexia 01/2017
1	Microaneurysm 01/2017
1	Diarrhea 01/2017
1	Muscle Cramp (Cramp) 01/2017
1	Ovarian Epithelial Carcinoma 01/2017

Drug/Important Bio-Agent (IBA)

33	Ranibizumab (Lucentis)FDA Link 01/2019 - 10/2006
30	afliberceptIBA 01/2022 - 06/2011
29	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 10/2006
17	Retinaldehyde (Retinal)IBA 01/2022 - 03/2007
10	Fluorescein (Funduscein)FDA LinkGeneric 01/2022 - 01/2013
9	salicylhydroxamic acid (SHAM)IBA 05/2021 - 10/2006
4	CytokinesIBA 10/2022 - 06/2010
4	Fluocinolone Acetonide (Capex)FDA LinkGeneric 03/2013 - 07/2010
4	Verteporfin (Visudyne)FDA Link 10/2010 - 10/2006
3	Endothelial Growth FactorsIBA 01/2022 - 10/2010
3	brolucizumabIBA 01/2022 - 01/2020
3	Pharmaceutical PreparationsIBA 10/2018 - 08/2010
3	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 01/2018 - 01/2018
3	phenoxodiolIBA 08/2010 - 07/2005
2	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2021
2	MetalsIBA 08/2021 - 05/2005
2	OxidesIBA 08/2021 - 01/2018
2	CopperIBA 08/2021 - 01/2018
2	N-acetyltryptophanamide (NATA)IBA 01/2018 - 08/2017
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2018 - 04/2012
2	SuspensionsIBA 01/2018 - 09/2010
2	CaspasesIBA 01/2017 - 09/2011
2	Anti-Bacterial Agents (Antibiotics)IBA 07/2016 - 04/2013
2	Bevacizumab (Avastin)FDA Link 01/2016 - 10/2010
2	Hormones (Hormone)IBA 02/2013 - 07/2005
2	Gemcitabine FDA Link 09/2011 - 04/2009
2	triphendiolIBA 09/2011 - 04/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2010 - 01/2003
2	IsoflavonesIBA 04/2009 - 07/2005
2	FlavonoidsIBA 04/2009 - 07/2005
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2009 - 12/2007
2	Monoclonal AntibodiesIBA 10/2006 - 10/2006
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2005 - 01/2003
1	Neurofibromin 2 (Merlin)IBA 01/2022
1	Leukotriene B4IBA 01/2022
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2022
1	Complement C3 (C3 Complement)IBA 01/2020
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2020
1	pegcetacoplanIBA 01/2020
1	Immunoglobulin FragmentsIBA 01/2020
1	ClenbuterolIBA 01/2018
1	MyogeninIBA 01/2018
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 01/2018
1	Hemoglobins (Hemoglobin)IBA 09/2017
1	Carboplatin (JM8)FDA LinkGeneric 01/2017
1	Alanine Transaminase (SGPT)IBA 01/2017
1	Tyrosine Kinase InhibitorsIBA 01/2017
1	Transaminases (Aminotransferases)IBA 01/2017
1	4- (para- hydroxyphenyl)- 7,4'- dihydroxy- 3',5'- dimethoxy- 8- methylisoflavanIBA 01/2017
1	Cisplatin (Platino)FDA LinkGeneric 01/2017
1	CoagulaseIBA 07/2016
1	Prednisone (Sone)FDA LinkGeneric 01/2016

Therapy/Procedure

19	Therapeutics 01/2022 - 07/2005
16	Injections 09/2021 - 10/2006
13	Lasers (Laser) 01/2019 - 03/2007
9	Light Coagulation 10/2018 - 03/2007
7	Intravitreal Injections 01/2021 - 10/2006
4	Photochemotherapy (Photodynamic Therapy) 10/2010 - 10/2006
3	Intraocular Injections 10/2011 - 06/2010
2	Drug Therapy (Chemotherapy) 07/2005 - 01/2003
1	Retreatment 01/2018
1	Glycemic Control 09/2017
1	Antibiotic Prophylaxis 07/2016
1	Solid-State Lasers 01/2016